Controlled-Release Levodopa Dosing for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral levodopa formulations struggle with rapid metabolism, leading to unpredictable plasma levels and motor fluctuations in Parkinson's disease patients, making it difficult to achieve steady plasma concentrations and effective symptom management with existing twice or thrice daily dosing regimens.
Innovation Solution
A dosing regimen involving controlled release levodopa compositions administered twice or thrice daily, with each dose ranging from 140 to 700 mg, allowing for sustained plasma levels and reduced motor fluctuations, and incorporating immediate and controlled release components to optimize absorption and minimize adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral levodopa is administered to treat Parkinson's disease, then motor symptoms are improved, but plasma levels become unpredictable and motor fluctuations occur
Solution Approach 1:
The levodopa dosage is divided into multiple smaller doses administered throughout the day, with each dose containing levodopa combined with carbidopa. This segmentation prevents rapid metabolism and maintains stable plasma levels, reducing motor fluctuations while effectively managing symptoms.
Solution Approach 2:
Carbidopa is introduced as an intermediary substance that inhibits peripheral decarboxylation of levodopa. This mediator allows more levodopa to reach the brain by preventing its breakdown in the periphery, thereby stabilizing plasma levels and improving symptom management consistency.
2Reliability
If levodopa is administered frequently to maintain plasma levels, then symptom control improves, but adherence becomes difficult
Solution Approach 1:
Levodopa and carbidopa are combined into a single oral composition that can be administered together. This merging allows for consistent symptom control through coordinated delivery of both substances while simplifying the dosing regimen to once or twice daily, improving patient adherence.
Solution Approach 2:
The composition is designed to provide continuous therapeutic action through sustained release mechanisms, maintaining effective plasma levels of levodopa over extended periods. This continuity enables less frequent dosing while preserving consistent symptom control.
3Productivity
If high doses of levodopa are administered to improve motor function, then symptom relief increases, but adverse effects such as dyskinesia and nausea increase
Solution Approach 1:
The dosing regimen utilizes lower individual doses of levodopa administered at optimized intervals rather than high single doses. This parameter change in dosing strategy achieves effective motor function improvement while staying below thresholds that trigger adverse effects like dyskinesia and nausea.
Solution Approach 2:
Carbidopa acts as a protective intermediary that reduces peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain at lower doses. This mediator effect improves motor function while minimizing adverse reactions by optimizing the distribution and metabolism of levodopa.
Data Source
AI summary
The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.